Lipid oil nanodroplets for hydrophobic drug delivery

Delivery of anti-cancer drugs to tumours is a fundamental requirement for cancer treatment. However, failure of drugs to reach tumours at sufficient concentrations due to poor bioavailability, rapid metabolism and elimination compromises effective treatment. A substantial number of potent anti-cance...

Full description

Saved in:
Bibliographic Details
Main Author Charalambous, Antonia
Format Dissertation
LanguageEnglish
Published University of Leeds 2018
Online AccessGet full text

Cover

Loading…
Abstract Delivery of anti-cancer drugs to tumours is a fundamental requirement for cancer treatment. However, failure of drugs to reach tumours at sufficient concentrations due to poor bioavailability, rapid metabolism and elimination compromises effective treatment. A substantial number of potent anti-cancer drugs, exhibit hydrophobic properties that hinder their clinical use. Therefore, there is an urgent need for the development of a hydrophobic drug delivery system (DDS) that aims to effectively deliver and controllably trigger the release of these agents. This may improve drug bioavailability, efficacy and reduce severe side effects. Lipid-Oil-NanoDroplets (LONDs) are nanosized nanoemulsions and are proposed as a novel hydrophobic DDS for colorectal cancer (CRC) treatment. LONDs were produced using a two-step high pressure homogenisation process, producing LONDs with size ranges between 100-300 nm. The hydrophobic vascular disrupting agent Combretastatin A4 (CA4) was encapsulated and used as a proof-of-concept for LOND evaluation in vitro and in vivo. CA4 was dispersed in triacetin or tripropionin oil to form the LOND core, stabilised by a phospholipid-shell. Using a microfluidic production platform, CA4 LONDs were attached on-chip to gas-filled, phospholipid-shelled therapeutic microbubbles (thMBs). CA4 thMBs were targeted to vascular endothelial growth factor receptor 2 (VEGFR-2) and used as LOND delivery vehicles. An external ultrasound (US) destruction pulse applied at the tumour site was used to trigger targeted release and enhance delivery. This project showed CA4 release and/or uptake from LONDs in both endothelial and human CRC cells by immunofluorescence and flow cytometry. Intratumoural delivery of CA4 LONDs was observed and quantified in CRC xenografts using liquid chromatography tandem mass spectrometry (LS-MS/MS). Administration of CA4 LONDs resulted in a modest tumour growth inhibition in vivo, while a reduction in tumour perfusion was observed with CA4 thMBs. Combination therapy of CA4 thMBs with a chemotherapeutic agent, irinotecan, further reduced tumour growth compared to irinotecan alone, potentially through reduction in tumour perfusion. These results suggest that LONDs may serve as a novel hydrophobic DDS, while thMBs could further enhance tumour specific delivery.
AbstractList Delivery of anti-cancer drugs to tumours is a fundamental requirement for cancer treatment. However, failure of drugs to reach tumours at sufficient concentrations due to poor bioavailability, rapid metabolism and elimination compromises effective treatment. A substantial number of potent anti-cancer drugs, exhibit hydrophobic properties that hinder their clinical use. Therefore, there is an urgent need for the development of a hydrophobic drug delivery system (DDS) that aims to effectively deliver and controllably trigger the release of these agents. This may improve drug bioavailability, efficacy and reduce severe side effects. Lipid-Oil-NanoDroplets (LONDs) are nanosized nanoemulsions and are proposed as a novel hydrophobic DDS for colorectal cancer (CRC) treatment. LONDs were produced using a two-step high pressure homogenisation process, producing LONDs with size ranges between 100-300 nm. The hydrophobic vascular disrupting agent Combretastatin A4 (CA4) was encapsulated and used as a proof-of-concept for LOND evaluation in vitro and in vivo. CA4 was dispersed in triacetin or tripropionin oil to form the LOND core, stabilised by a phospholipid-shell. Using a microfluidic production platform, CA4 LONDs were attached on-chip to gas-filled, phospholipid-shelled therapeutic microbubbles (thMBs). CA4 thMBs were targeted to vascular endothelial growth factor receptor 2 (VEGFR-2) and used as LOND delivery vehicles. An external ultrasound (US) destruction pulse applied at the tumour site was used to trigger targeted release and enhance delivery. This project showed CA4 release and/or uptake from LONDs in both endothelial and human CRC cells by immunofluorescence and flow cytometry. Intratumoural delivery of CA4 LONDs was observed and quantified in CRC xenografts using liquid chromatography tandem mass spectrometry (LS-MS/MS). Administration of CA4 LONDs resulted in a modest tumour growth inhibition in vivo, while a reduction in tumour perfusion was observed with CA4 thMBs. Combination therapy of CA4 thMBs with a chemotherapeutic agent, irinotecan, further reduced tumour growth compared to irinotecan alone, potentially through reduction in tumour perfusion. These results suggest that LONDs may serve as a novel hydrophobic DDS, while thMBs could further enhance tumour specific delivery.
Author Charalambous, Antonia
Author_xml – sequence: 1
  fullname: Charalambous, Antonia
BookMark eNrjYmDJy89L5WQw8cksyExRyM_MUchLzMtPKcovyEktKVZIyy9SyKgEcTPykzKTFVKKStMVUlJzMstSiyp5GFjTEnOKU3mhNDeDkZtriLOHblJRZklmcUZOZlJRYlFlfGpJRn5xfH5iJpSVlBNfmh1vbmphbGBpTJYmAI8DP2w
ContentType Dissertation
DBID ABQQS
LLH
DEWEY 610
DatabaseName EThOS: Electronic Theses Online Service (Full Text)
EThOS: Electronic Theses Online Service
DatabaseTitleList
Database_xml – sequence: 1
  dbid: LLH
  name: EThOS: Electronic Theses Online Service
  url: http://ethos.bl.uk/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DissertationAdvisor Coletta, Louise
Carr, Ian
Markham, Alexander
Bonthron, David
DissertationAdvisor_xml – sequence: 1
  fullname: Markham, Alexander
– sequence: 2
  fullname: Coletta, Louise
– sequence: 3
  fullname: Bonthron, David
– sequence: 4
  fullname: Carr, Ian
DissertationDegree Thesis (Ph.D.)
DissertationSchool University of Leeds
ExternalDocumentID oai_ethos_bl_uk_758309
GroupedDBID ABQQS
LLH
ID FETCH-britishlibrary_ethos_oai_ethos_bl_uk_7583093
IEDL.DBID LLH
IngestDate Tue Apr 04 22:45:42 EDT 2023
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-britishlibrary_ethos_oai_ethos_bl_uk_7583093
Notes 0000000474310829
OpenAccessLink http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.758309
ParticipantIDs britishlibrary_ethos_oai_ethos_bl_uk_758309
PublicationCentury 2000
PublicationDate 2018
PublicationDateYYYYMMDD 2018-01-01
PublicationDate_xml – year: 2018
  text: 2018
PublicationDecade 2010
PublicationYear 2018
Publisher University of Leeds
Publisher_xml – name: University of Leeds
Score 3.6609874
Snippet Delivery of anti-cancer drugs to tumours is a fundamental requirement for cancer treatment. However, failure of drugs to reach tumours at sufficient...
SourceID britishlibrary
SourceType Open Access Repository
Title Lipid oil nanodroplets for hydrophobic drug delivery
URI http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.758309
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQSU5MAvWj03QNLCyBHZRkY1PQQFOqrmGKiXGaoUkKsA4GDej7-pl5hJp4RZhGQK_6Ao3plmTkF-sl5YB2UfmDzp50AS-kLNZLybcvzcyzLc0GSUJUAVu6xqCte6xGwDYJ6PICHx8Pbga-JMhhQNBBEKTKwk2QgccFaZJbiIEpNU-YgcMXOoktwmACui86RSE_M0chLzEvP6UItIa7pFgB2HxUyKgEcTPykzKTFVKKStMVUlJzQCsnKkUZjNxcQ5w9dFEtjgc7Mh50ejOElZQTX5odD3G0sRgDC7B3nyrBoGBpnpwK7FYkppiDugImqRYWkCNqUi3SUs3MUlIkGbRJMFiKJNXSDFzA-t8CMqIgw8BSUlSaKgusY0uS5MChCQB9dYtN
link.rule.ids 230,311,780,885,4052,26562
linkProvider British Library Board
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adissertation&rft.genre=dissertation&rft.title=Lipid+oil+nanodroplets+for+hydrophobic+drug+delivery&rft.DBID=ABQQS%3BLLH&rft.au=Charalambous%2C+Antonia&rft.date=2018&rft.pub=University+of+Leeds&rft.advisor=Coletta%2C+Louise&rft.inst=University+of+Leeds&rft.externalDBID=n%2Fa&rft.externalDocID=oai_ethos_bl_uk_758309